Analysis of U.S. Patent 12,042,474: Solid Form of Rimegepant
This report analyzes U.S. Patent 12,042,474, titled "SOLID FORM OF RIMEGEPANT," focusing on its scope, claims, and the surrounding patent landscape. The patent protects a specific crystalline form of rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. This analysis is critical for stakeholders in the migraine therapeutic market, including pharmaceutical companies, investors, and R&D strategists.
What is the Scope and Key Innovation of U.S. Patent 12,042,474?
U.S. Patent 12,042,474, issued on June 11, 2024, to Biohaven Pharmaceuticals Holding Company Ltd., claims a specific crystalline form of rimegepant, designated as Form I. Rimegepant is the active pharmaceutical ingredient in NURTEC® ODT, a medication approved for the acute treatment of migraine with or without aura and for the preventive treatment of episodic migraine [1].
The core innovation protected by this patent lies in the identification, isolation, and characterization of a specific crystalline polymorph of rimegepant. Polymorphs are different crystalline structures of the same chemical compound. These distinct structures can have significantly different physical properties, including solubility, dissolution rate, stability, and bioavailability. By protecting a specific solid form, the patent aims to secure market exclusivity for rimegepant formulations that utilize this advantageous crystalline structure.
The patent specifically describes Form I as being characterized by its X-ray powder diffraction (XRPD) pattern, which exhibits characteristic peaks at specific 2-theta angles. Key peaks listed in the patent include approximately 5.1, 7.7, 15.4, 16.6, 19.4, and 20.4 degrees 2-theta. It also describes the solid form by its differential scanning calorimetry (DSC) thermogram, showing a specific endotherm with a peak temperature of approximately 170°C, and its thermogravimetric analysis (TGA) profile, which indicates minimal weight loss below 160°C [1].
These characteristics define Form I, distinguishing it from other potential solid forms of rimegepant. The inventors claim that this specific crystalline form offers advantages in terms of stability and manufacturability, which are crucial for pharmaceutical development and commercialization.
What are the Key Claims of the Patent?
U.S. Patent 12,042,474 includes several claims that define the scope of protection. The most critical claims are directed towards the specific crystalline form of rimegepant itself and pharmaceutical compositions containing it.
Claim 1: This independent claim is central to the patent. It claims "A crystalline form of rimegepant designated as Form I" [1]. The claim further defines Form I by its XRPD pattern, specifying the presence of diffraction peaks at particular 2-theta values. This claim establishes direct protection for the physical substance.
Claim 2: This claim depends on Claim 1 and further defines Form I by its DSC thermogram, specifying a particular endotherm peak temperature. This provides additional characterizing data and strengthens the definition of Form I [1].
Claim 3: This claim also depends on Claim 1 and further defines Form I by its TGA profile, detailing minimal weight loss below a certain temperature. This further refines the characterization of the specific crystalline form [1].
Claim 4: This claim is an independent claim directed towards pharmaceutical compositions. It claims "A pharmaceutical composition comprising the crystalline form of rimegepant of claim 1" [1]. This claim extends protection to drug products that incorporate Form I, regardless of the specific formulation, as long as Form I is present.
Dependent Claims (e.g., Claims 5 onwards): The patent likely includes additional dependent claims that further specify characteristics of the pharmaceutical compositions. These might include claims related to specific excipients, dosages, or methods of administration of the drug product containing Form I. For example, a claim might specify a composition comprising Form I and a pharmaceutically acceptable carrier [1].
The breadth of these claims is significant. Claim 1 protects the specific crystalline entity itself, while Claim 4 protects any pharmaceutical composition that uses this crystalline form. This dual protection strategy aims to prevent competitors from using the advantageous solid form in any drug product, effectively creating a barrier to entry for generic versions of rimegepant if they rely on Form I.
What is the Patent Landscape for Rimegepant and CGRP Antagonists?
The patent landscape surrounding rimegepant is complex, involving multiple patents covering the compound itself, its synthesis, specific crystalline forms, and various therapeutic uses. U.S. Patent 12,042,474 is one piece of this broader intellectual property strategy.
Core Compound Patents: The initial discovery and synthesis of rimegepant are protected by earlier composition of matter patents. These patents generally expire sooner but provide foundational protection. For instance, U.S. Patent 9,102,600, also assigned to Biohaven Pharmaceuticals, covers rimegepant and related compounds [2].
Polymorph Patents: U.S. Patent 12,042,474 is part of a strategy to secure extended exclusivity through solid-form patents. Pharmaceutical companies frequently file patents on new, advantageous crystalline forms of existing drugs to extend market protection beyond the expiry of the original composition of matter patents. This strategy is common for blockbuster drugs where the value of extended exclusivity is substantial.
Formulation and Method of Use Patents: Biohaven Pharmaceuticals also holds patents related to specific formulations of rimegepant, such as orally disintegrating tablets (ODT), and methods of treating specific conditions like migraine. These patents can further fortify market exclusivity. For example, patents related to the ODT formulation would protect the specific delivery system of NURTEC® ODT.
Competitive Landscape (CGRP Antagonists): Rimegepant belongs to the class of CGRP receptor antagonists. This therapeutic area is highly competitive, with several other drugs and drug candidates. Key competitors include:
- Ubrogepant (UBRElvy® by AbbVie): Another CGRP receptor antagonist for acute migraine. AbbVie also likely possesses a portfolio of patents covering ubrogepant, its forms, and uses.
- Gepants (e.g., Zavegepant nasal spray by Biohaven/Pfizer): This includes other CGRP antagonists with different administration routes and potentially different patent protection strategies. Zavegepant, for instance, received FDA approval and is covered by its own set of patents.
- Grams (e.g., Erenumab, Fremanezumab, Galcanezumab): These are monoclonal antibodies that target CGRP or its receptor, used primarily for migraine prevention. They operate under a different patent protection framework, typically involving patents on the antibody sequence, manufacturing process, and therapeutic indications.
The presence of numerous patents across different aspects of rimegepant and its competitors creates a complex "patent thicket." Companies seeking to enter the market with a generic version of rimegepant must navigate this thicket carefully, potentially challenging existing patents or developing non-infringing formulations or synthetic routes.
What are the Potential Implications of this Patent for Market Exclusivity?
U.S. Patent 12,042,474 has significant implications for the market exclusivity of rimegepant, particularly concerning potential generic competition.
Extension of Market Protection: This patent, issued in 2024, provides a new layer of protection for rimegepant. While the original composition of matter patents for rimegepant may begin to expire in the coming years, the solid-form patent provides exclusivity for products utilizing Form I. The term of this patent is 20 years from its filing date, which was May 4, 2021 [1]. This means it will expire in 2041, potentially extending market exclusivity for rimegepant well beyond the expiration of earlier patents.
Barriers to Generic Entry: For a generic manufacturer to launch a bioequivalent version of NURTEC® ODT, they would typically need to avoid infringing on all valid and in-force patents. If a generic product utilizes the crystalline Form I of rimegepant, it would directly infringe on Claim 1 and Claim 4 of U.S. Patent 12,042,474. Generic companies would therefore need to:
- Develop an alternative crystalline form of rimegepant that does not infringe on Form I claims.
- Develop a non-infringing synthetic process that yields a different crystalline form.
- Challenge the validity of U.S. Patent 12,042,474.
Developing and characterizing a new crystalline form that offers comparable stability and manufacturability to Form I can be a significant undertaking and may also be subject to its own patent protection.
Strategic Value of Solid Form Patents: This patent highlights the strategic importance of solid-form intellectual property in the pharmaceutical industry. Protecting advantageous crystalline forms is a common strategy to extend the commercial life of successful drugs, particularly in competitive therapeutic areas like migraine treatment. The value of this patent is directly tied to the market performance of NURTEC® ODT and the potential for generic erosion.
Potential for Litigation: The existence of this patent increases the likelihood of patent litigation. Generic manufacturers seeking to launch will likely challenge its validity, citing prior art or arguing that the claimed form is not novel or non-obvious. Biohaven Pharmaceuticals will likely defend its patent vigorously.
Impact on R&D and Investment: For R&D departments and investors, this patent signifies an extended period of potential market exclusivity for Biohaven Pharmaceuticals and its partners concerning rimegepant formulated with Form I. It also emphasizes the need for thorough patent landscape analysis when considering investments in the migraine therapeutic space, as solid-form patents can significantly alter the competitive dynamics and market entry timelines.
What is the Status of Patent 12,042,474 and Related Filings?
U.S. Patent 12,042,474 was officially issued by the United States Patent and Trademark Office (USPTO) on June 11, 2024 [1]. The patent has a filing date of May 4, 2021. The patent term is 20 years from the filing date, meaning it will expire in 2041, barring any extensions or challenges.
Prosecution History: The prosecution history of this patent at the USPTO provides insights into its development. During examination, patent examiners assess novelty, non-obviousness, and enablement. The inventor(s) would have responded to office actions, potentially amending claims or providing further arguments and data to overcome rejections. Understanding this history can be valuable for potential challengers, as it may reveal weaknesses or concessions made during prosecution.
International Filings: It is standard practice for pharmaceutical companies to seek patent protection in multiple jurisdictions. Biohaven Pharmaceuticals has likely filed corresponding patent applications in major pharmaceutical markets worldwide, including Europe, Japan, China, and Canada. The status and claims of these international filings would need to be assessed separately to understand the global patent protection for Form I of rimegepant.
Related Applications: The patent family associated with U.S. Patent 12,042,474 may include other pending applications or granted patents covering different aspects of Form I or other crystalline forms. For instance, there might be applications covering specific manufacturing processes for Form I or alternative crystalline forms of rimegepant. A comprehensive patent landscape analysis would typically examine the entire patent family.
Post-Grant Proceedings: Following the issuance of a patent, it is subject to potential challenges through post-grant proceedings, such as inter partes review (IPR) or post-grant review (PGR) at the USPTO, or litigation in federal courts. These proceedings allow third parties to challenge the validity of a granted patent.
Current Status and Enforcement: As of the issuance date, U.S. Patent 12,042,474 is in force. Biohaven Pharmaceuticals is entitled to enforce its rights against infringers. The company would monitor the market for any products that appear to infringe on its claims and would consider legal action to protect its exclusivity.
Table 1: Key Information for U.S. Patent 12,042,474
| Attribute |
Value |
| Patent Number |
U.S. Patent 12,042,474 |
| Title |
SOLID FORM OF RIMEGEPANT |
| Assignee |
Biohaven Pharmaceuticals Holding Company Ltd. |
| Issue Date |
June 11, 2024 |
| Filing Date |
May 4, 2021 |
| Expiration Date |
May 4, 2041 (20 years from filing date) |
| Core Subject Matter |
Specific crystalline form of rimegepant (Form I) and pharmaceutical compositions containing Form I. |
| Key Characterization |
XRPD, DSC, TGA |
Key Takeaways
- U.S. Patent 12,042,474 protects a specific crystalline form of rimegepant, designated as Form I, along with pharmaceutical compositions containing it.
- This solid-form patent provides a critical layer of market exclusivity, extending protection for rimegepant beyond the expiry of earlier composition of matter patents.
- The patent defines Form I through specific characterization data, including XRPD, DSC, and TGA patterns, creating a clear technical standard for infringement.
- The issued patent, with an expiration date of 2041, presents a significant barrier for generic manufacturers seeking to launch products using the protected crystalline form.
- The CGRP antagonist market is competitive, and solid-form patents like this are a common strategy to extend market exclusivity and deter generic entry.
Frequently Asked Questions
-
What is the primary purpose of protecting a specific crystalline form of a drug like rimegepant?
Protecting a specific crystalline form aims to extend market exclusivity. Different crystalline forms (polymorphs) can have distinct physical properties, such as stability and dissolution rates, which can impact drug performance and manufacturability. By patenting an advantageous form, the patent holder can prevent competitors from using that specific form, even if the original compound patent has expired.
-
How does U.S. Patent 12,042,474 differ from the initial patents covering rimegepant?
Initial patents typically cover the composition of matter, meaning the chemical compound itself. U.S. Patent 12,042,474 covers a specific physical manifestation (crystalline form) of that compound. This is a subsequent patent that can provide protection for a longer period or under different conditions than the original compound patent.
-
What are the implications for generic manufacturers who wish to produce a rimegepant product after the compound patent expires?
Generic manufacturers must ensure their product does not infringe on any valid and enforceable patents. If U.S. Patent 12,042,474 is still in force and considered valid, a generic product that utilizes the crystalline Form I of rimegepant would infringe. Generic companies would need to develop alternative crystalline forms, non-infringing synthetic routes, or challenge the validity of this patent.
-
What are the key characteristics used to define Form I in U.S. Patent 12,042,474?
Form I is primarily defined by its X-ray powder diffraction (XRPD) pattern, which shows characteristic peaks at specific 2-theta angles. Additional characterization is provided by its differential scanning calorimetry (DSC) thermogram, showing a specific endotherm, and its thermogravimetric analysis (TGA) profile, indicating minimal weight loss below 160°C.
-
Can other crystalline forms of rimegepant exist and be patented?
Yes, a single drug compound can often exist in multiple crystalline forms (polymorphs). If a company discovers another crystalline form with distinct, advantageous properties and meets patentability criteria (novelty, non-obviousness), it can be patented separately. This can lead to a complex "patent thicket" where multiple patents cover different aspects of the same drug.
Citations
[1] Biohaven Pharmaceuticals Holding Company Ltd. (2024). U.S. Patent No. 12,042,474. United States Patent and Trademark Office.
[2] Biohaven Pharmaceuticals Holding Company Ltd. (2015). U.S. Patent No. 9,102,600. United States Patent and Trademark Office.
